BIOMAT Database Logo BIOMAT Database Logo

Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients. 2012

Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Department of Infectious Diseases Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China.

BACKGROUND The pharmacokinetics of zidovudine (AZT) are possibly influenced by weight, age, sex, liver and renal functions, severity of disease, and ethnicity. Currently, little information is available on the steady-state pharmacokinetics of AZT in Chinese HIV-infected patients. The current study aimed to characterize the steady-state pharmacokinetics of AZT in a Chinese set-up. METHODS Eleven Chinese HIV-infected patients were involved in the steady-state pharmacokinetic study. In total, 300 mg of AZT, as a part of combination therapy, was given to patients, and serial blood samples were collected for 12 hours. The samples were measured by a high-performance liquid chromatography (HPLC) assay, and the results were analyzed by both the non-compartment model and the one-compartment model. RESULTS The C(max) of AZT in Chinese patients was higher than that in non-Asian patients. The half-life of AZT, analyzed by the non-compartment model (P = 0.02), in male patients ((1.02 ± 0.22) hours) was shorter than that of AZT in female patients ((1.55 ± 0.29) hours). The AZT clearance, analyzed by the one-compartment model (P = 0.045), in male patients ((262.60 ± 28.13) L/h) was higher than that in female patients ((195.85 ± 60.51) L/h). CONCLUSIONS The present study provides valuable information for the clinical practice of AZT-based highly active antiretroviral therapy in a Chinese set-up.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D044466 Asian People Persons having origins in any of the Asian racial groups of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. Note that OMB category ASIAN is available for United States population groups. Race and ethnicity terms, as used in the federal government, are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. Asian Continental Ancestry Group,Asian Person,Asiatic Race,Mongoloid Race,Asian Peoples,Asian Persons,Asiatic Races,Mongoloid Races,People, Asian,Person, Asian,Race, Asiatic,Race, Mongoloid
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.
January 2010, HIV clinical trials,
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
September 2011, Antimicrobial agents and chemotherapy,
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.
July 2017, Expert review of clinical pharmacology,
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
January 2005, Antiviral therapy,
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
November 2004, Journal of acquired immune deficiency syndromes (1999),
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India.
December 2007, Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002),
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
October 2004, Antiviral therapy,
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease.
January 1995, Blood purification,
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.
June 1992, British journal of clinical pharmacology,
Li-Feng Liu, and Lu Wang, and Qiang Fu, and Zhu Zhu, and Jing Xie, and Yang Han, and Zheng-Yin Liu, and Min Ye, and Tai-Sheng Li
Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.
May 2014, Clinical pharmacology in drug development,
Copied contents to your clipboard!